Janus Henderson Group PLC Has $537,000 Stock Holdings in Mineralys Therapeutics, Inc. $MLYS

Key Points

• Janus Henderson Group cut its Mineralys Therapeutics stake by 98.4% in the first quarter, selling 1.19 million shares and retaining 19,848 shares valued at approximately $537,000.
• Institutional ownership remains high at 84.46%, while several other investors—including Royal Bank of Canada and Russell Investments—substantially increased their positions.
• Analyst sentiment is mixed but leans positive: six analysts rate the stock a Buy, one rates it Hold, and one rates it Sell, producing a “Moderate Buy” consensus and a $49.33 average price target versus the reported $27.38 share price.

Janus Henderson Group PLC decreased its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 98.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,848 shares of the company's stock after selling 1,193,417 shares during the period. Janus Henderson Group PLC's holdings in Mineralys Therapeutics were worth $537,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Navalign LLC acquired a new position in shares of Mineralys Therapeutics in the 4th quarter worth approximately $33,000. KBC Group NV acquired a new stake in Mineralys Therapeutics in the 1st quarter valued at $33,000. Royal Bank of Canada grew its position in Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after acquiring an additional 1,107 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company's stock valued at $76,000 after acquiring an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Mineralys Therapeutics by 14,091.3% during the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock worth $124,000 after acquiring an additional 3,241 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MLYS. HC Wainwright reissued a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They set a "buy" rating for the company. Jefferies Financial Group reaffirmed a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, Wall Street Zen lowered shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $49.33.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock opened at $27.38 on Tuesday. The firm has a market cap of $2.26 billion, a P/E ratio of -13.36 and a beta of 0.68. The firm has a 50 day simple moving average of $26.41 and a 200 day simple moving average of $27.68. Mineralys Therapeutics, Inc. has a fifty-two week low of $12.59 and a fifty-two week high of $47.65.

Insider Transactions at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 14,056 shares of the company's stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48. Following the transaction, the insider owned 63,443 shares of the company's stock, valued at $1,813,200.94. This represents a 18.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the firm's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the completion of the transaction, the chief executive officer owned 614,321 shares in the company, valued at approximately $16,058,350.94. This represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 229,199 shares of company stock valued at $5,967,423 over the last 90 days. 18.94% of the stock is currently owned by corporate insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source